Lipid nanoparticles for gene therapy

February 14, 2017

Lipid nanoparticles (SLNs and NLCs) are regarded as highly promising systems for delivering nucleic acids in gene therapy. Until now, viral systems have been the most effective method for delivering genetic matter but they pose significant safety problems. "Non-viral vectors, including SLNs and NLCs, are less effective but much safer even though their effectiveness has increased significantly in recent years", pointed out Alicia Rodrí­guez, Marí­a Ángeles Soliní­s and Ana del Pozo, authors of the article published in the European Journal of Pharmaceutics and Biopharmaceutics.

This review article describes these systems and their main advantages in gene therapy, such as their capacity to protect the gene material against degradation, to facilitate cell and nucleus internalisation and to boost the transfection process. "What is more, the nanoparticles are made up of biocompatible, biodegradable materials, they are easy to produce on a large scale, they can be sterilised and freeze-dried and are very stable both in biological fluids and in storage," explained the researchers.

This review also includes the main diseases in which lipid nanoparticles are being applied, generally on the preclinical level: degenerative diseases of the retina, infectious diseases, metabolic disorders, and cancer, among others. "At PharmaNanoGene we are working on the design and evaluation of SLNs for treating some of these diseases using gene therapy. We are studying the relationship between formulation factors and the processes involving the intracellular internalisation and disposition of the genetic material that condition the effectiveness of the vectors and which is essential in the optimisation process, and for the first time we have demonstrated the capacity of SLNs to induce the synthesis of a protein following their intravenous administration in mice," they stressed.

The publication also includes other pieces of work by this UPV/EHU research group on the application of SLNs in the treatment of rare diseases, such as chromosome-X-linked juvenile retinoschisis, a disorder in which the retina becomes destructured due to a deficiency in the protein retinoschisin. "One of the main achievements of our studies in this field has been to demonstrate, also for the first time, the capacity of a non-viral vector to transfect the retina of animals lacking the gene that encodes this protein and partially restore its structure, showing than non-viral gene therapy is a viable, promising therapeutic tool for treating degenerative disorders of the retina," specified the researchers.

The application of SLNs for treating Fabry disease, a serious, multi-system metabolic disorder of a hereditary nature, has also been studied at PharmaNanoGene. "This is a monogenic disease linked to the X-chromosome which is caused by various gene mutations in the gene that encodes the -galactosidase A (-Gal A) enzyme. In cell models of this disease we have demonstrated the capacity of SLNs to induce the synthesis of -Gal A". They have also reviewed the application of lipid nanoparticles to the treatment of infectious diseases: "Our work in this field shows that SLNs with RNA interference are capable of inhibiting a replicon of the hepatitis C virus in vitro, which was used as proof-of-concept of the use of SLN-based vectors as a new therapeutic strategy for treating this infection and others related to it".
-end-
The research group

The UPV/EHU's Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene) is attached to the Department of Pharmacy and Food Sciences of the Faculty of Pharmacy and to the Lascaray Ikergunea (Research Centre). It is a consolidated group of the Basque University System whose research activity comes within the framework of drug design and evaluation. One of its main lines of research revolves around the development of new systems of drug delivery based on micro- and nanoparticles, more specifically, around lipid nanoparticles to increase the oral absorption of poorly-soluble drugs, and for the administration of nucleic acids (gene therapy).

Bibliographical reference

Del Pozo-Rodrí­guez, A., Solinis, M.A., Rodríguez Gascón, A. Applications of lipid nanoparticles in gene therapy. European Journal of Pharmaceutics and Biopharmaceutics. Volume 109, December 2016, 184-193. DOI: http://dx.doi.org/10.1016/j.ejpb.2016.10.016

University of the Basque Country

Related Nanoparticles Articles from Brightsurf:

An ionic forcefield for nanoparticles
Nanoparticles are promising drug delivery tools but they struggle to get past the immune system's first line of defense: proteins in the blood serum that tag potential invaders.

Phytoplankton disturbed by nanoparticles
Products derived from nanotechnology are efficient and highly sought-after, yet their effects on the environment are still poorly understood.

How to get more cancer-fighting nanoparticles to where they are needed
University of Toronto Engineering researchers have discovered a dose threshold that greatly increases the delivery of cancer-fighting drugs into a tumour.

Nanoparticles: Acidic alert
Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich have synthesized nanoparticles that can be induced by a change in pH to release a deadly dose of ionized iron within cells.

3D reconstructions of individual nanoparticles
Want to find out how to design and build materials atom by atom?

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.

Sweet nanoparticles trick kidney
Researchers engineer tiny particles with sugar molecules to prevent side effect in cancer therapy.

A megalibrary of nanoparticles
Using straightforward chemistry and a mix-and-match, modular strategy, researchers have developed a simple approach that could produce over 65,000 different types of complex nanoparticles.

Dialing up the heat on nanoparticles
Rapid progress in the field of metallic nanotechnology is sparking a science revolution that is likely to impact all areas of society, according to professor of physics Ventsislav Valev and his team at the University of Bath in the UK.

Illuminating the world of nanoparticles
Scientists at the Okinawa Institute of Science and Technology Graduate University (OIST) have developed a light-based device that can act as a biosensor, detecting biological substances in materials; for example, harmful pathogens in food samples.

Read More: Nanoparticles News and Nanoparticles Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.